Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...

Oral MYC condensate modulator drives tumor regression and stasis in preclinical modelsDisruption of MYC condensates enables ...

SemiTech's fair value price target has been marked slightly higher, shifting from US$104.62 to US$105.54, a move of about 0.9%. That tweak lines up with a wave of Street research that has pushed ...

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 ...

Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a ...

This study presents important findings for the understanding of central brain circuits that underlie nociception-induced escape. Using a laser-based nociception assay, chronic neuronal silencing, ...

Researchers reported favorable safety and tolerability for CS1 after 12 months of treatment in patients with pulmonary arterial hypertension.

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...

Marks First In-Human Clinical Study Demonstrating the Value of Immuno-Pharmacodynamics in the Assessment of Radioligand Therapy -- Novigenix AI Liquid Biopsy Platform Identifies Immune Activation ...

Three posters accepted at AACR 2026 highlighting SK Life Science Labs' targeted protein degradation pipeline -- Programs featured: selective p300 and PRMT5 degraders -- p300 degrader data demonstrate: ...

Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models ...